FARA’s campaign asks people affected by Friedreich’s ataxia to sign their open letter. The letter addresses the US regulator, FDA, and Reata pharmaceuticals. The letter requests Reata to submit a new drug application. It also asks the FDA to consider the approval of a new drug application for Omaveloxolone based on current evidence.
Omaveloxolone is not currently approved for normal clinical use.
Ataxia UK supports FARA’s campaign and has written a supporting letter to the FDA and Reata. Click here to read our letter.
UPDATE: The date for signing the letter has now passed, but if you are interested in knowing more visit: http://bit.ly/3i1Tk24
